| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcb746d7194a9f480041376d148a7cbb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1998-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6de17526fb232447a9d4fd202e00961d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68ed49b30d61a00081688ed0aec357c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8053d892a429ffce579fe97a8a0efe7b |
| publicationDate |
2003-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2205005-C2 |
| titleOfInvention |
Method and composition for peroral intake of taxanes by a patient |
| abstract |
FIELD: medicine. SUBSTANCE: the present method deals with peroral introduction of pharmaceutical agents which are poorly absorbed out of gastrointestinal tract. The method, also, deals with either elimination or decrease of hypersensitivity or allergic reactions in a patient on taxane-therapy, at treating diseases by taxane including peroral combined introduction of taxane and agent enhancing bioavailability in case of peroral intake without preliminary introduction of medicinal preparation to exclude hypersensitivity or allergic reactions, moreover, taxane reaches therapeutically active levels in a patient. EFFECT: higher bioavailability of the preparation suggested. 52 cl, 4 dwg |
| priorityDate |
1997-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |